International Clinical Trials in Oncology

Albania

• Non-Hodgkin's Lymphoma: MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
  Tirana; Research Site:
  
  
• Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
  Tirana; Research Site:
  
  

Algeria

• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Alger; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Alger; Research Site:
  
  

Argentina

• Breast Cancer: A Neoadjuvant Study of AC Followed by Ixabepilone or Paclitaxel in Early Stage Breast Cancer That is HER-2 Negative and Estrogen Receptor Negative
  Buenos Aires; Hospital Britanico De Buenos Aires
  
  
• Breast Cancer: A Neoadjuvant Study of AC Followed by Ixabepilone or Paclitaxel in Early Stage Breast Cancer That is HER-2 Negative and Estrogen Receptor Negative
  Buenos Aires; Corporacion Medica De General San Martin
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Buenos Aires ; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Cordoba; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  La Plata; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Mar Del Plata; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Mendoza; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  San Martin; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Santa Fe; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Buenos Aires ; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  La Plata; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Mar Del Plata; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Rosario; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Tucuman; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Buenos Aires ; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Chaco-Resistencia; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Córdoba; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  La Plata; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Mendoza; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Rosario; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Buenos Aires ; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Rosario; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Buenos Aires ; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  La Plata; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Pilar; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Santa Fe; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Buenos Aires ; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Bahia Blanca; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Buenos Aires ; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Córdoba; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  La Plata; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Rosario; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  San Miguel De Tucuman; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Santa Fe; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Buenos Aires ; Research Site:
  
  
• Gastric Cancer: A Study of Xeloda (Capecitabine) in Patients With Advanced or Metastatic Gastric Cancer
  Buenos Aires ; Research Site:
  
  
• Gastric Cancer: A Study of Xeloda (Capecitabine) in Patients With Advanced or Metastatic Gastric Cancer
  Rosario; Research Site:
  
  
• Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia (CLL)
  Buenos Aires ; Research Site:
  
  
• Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia (CLL)
  Córdoba; Research Site:
  
  
• Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia (CLL)
  La Plata; Research Site:
  
  
• Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia (CLL)
  Pilar; Research Site:
  
  
• Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia (CLL)
  Rosario; Research Site:
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  La Plata; Instituto Medico Platense
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Provincia de Buenos Aires; Instituto Medico
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Provincia de Santa Fe, Santa Fe; ISIS Clinica Especializada
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Buenos Aires; Hospital Militar Central
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Buenos Aires; Hospital Britanico de Buenos Aires
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Buenos Aires; Hospital General de Agudos Carlos G. Durand
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Buenos Aires; Hospital Municipal de Oncologia Maria Curie
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Cordoba; Hospital Privado de Cordoba S.A.
  
  
• Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
  Buenos Aires ; Research Site:
  
  
• Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
  La Plata; Research Site:
  
  
• Non-Hodgkin's Lymphoma: MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
  Bahia Blanca; Research Site:
  
  
• Non-Hodgkin's Lymphoma: MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
  Buenos Aires ; Research Site:
  
  
• Non-Hodgkin's Lymphoma: MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
  Córdoba; Research Site:
  
  
• Non-Hodgkin's Lymphoma: MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
  Corrientes; Research Site:
  
  
• Non-Hodgkin's Lymphoma: MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
  La Plata; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
  Buenos Aires ; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
  Chaco-Resistencia; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
  Córdoba; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
  Tucuman; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  Bahia Blanca; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  Buenos Aires ; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  Mendoza; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  San Miguel De Tucuman; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  Santa Fe; Research Site:
  
  
• Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
  Buenos Aires ; Research Site:
  
  
• Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
  Córdoba; Research Site:
  
  
• Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
  La Plata; Research Site:
  
  
• Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
  Salta; Research Site:
  
  
• Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
  Santa Fe; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Rosario; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  San Martín; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Villa Domínico; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Buenos Aires ; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Santa Fe; Research Site:
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Buenos Aires; Instituto Médico Especializado Alexander Fleming
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Cordoba; Instituto Oncologico De Cordoba
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Santa Fe; Isis Clinica Especializada
  
  

Australia

• Bladder Cancer: A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
  Adelaide, South Australia; Research Site
  
  
• Bladder Cancer: A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
  Sydney, New South Wales; Research Site
  
  
• Bladder Cancer: A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
  Waratah, New South Wales; Research Site
  
  
• Breast Cancer: A Continuation Study of Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer
  Brisbane; Research Site:
  
  
• Breast Cancer: A Continuation Study of Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer
  Fitzroy; Research Site:
  
  
• Breast Cancer: A Continuation Study of Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer
  Geelong; Research Site:
  
  
• Breast Cancer: A Continuation Study of Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer
  Liverpool; Research Site:
  
  
• Breast Cancer: A Continuation Study of Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer
  Parkville; Research Site:
  
  
• Breast Cancer: A Continuation Study of Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer
  Waratah; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Geelong; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Lismore; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Nambour; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Perth; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Port Macquarie; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Sydney; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Waratah; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Wollongong; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Adelaide; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Brisbane; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Fitzroy; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Melbourne; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Perth; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Sydney; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Adelaide; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Brisbane; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Darlinghurst; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  East Melbourne; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Frankston; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Gosford; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Lismore; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Maroochydore; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Perth; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Richmond; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  St. Leonards; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Sydney; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Wodonga; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Adelaide; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Brisbane; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Fitzroy; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Frankston; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Heidelberg; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Hobart; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Malvern; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Melbourne; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Parkville; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Perth; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Sydney; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Waratah; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Wodonga; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With HER2-Positive Advanced and/or Metastatic Breast Cancer
  Adelaide; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With HER2-Positive Advanced and/or Metastatic Breast Cancer
  Geelong; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With HER2-Positive Advanced and/or Metastatic Breast Cancer
  Melbourne; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With HER2-Positive Advanced and/or Metastatic Breast Cancer
  Perth; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With HER2-Positive Advanced and/or Metastatic Breast Cancer
  Southport; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With HER2-Positive Advanced and/or Metastatic Breast Cancer
  Sydney; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
  Geelong; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) Monotherapy in Women With Metastatic Breast Cancer
  Brisbane; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) Monotherapy in Women With Metastatic Breast Cancer
  Geelong; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) Monotherapy in Women With Metastatic Breast Cancer
  Parkville; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) Monotherapy in Women With Metastatic Breast Cancer
  Perth; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
  Geelong; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
  Perth; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Patients With Metastatic Breast Cancer
  Fitzroy; Research Site:
  
  
• Breast Cancer: A Study to Evaluate the Efficacy and Safety of Herceptin (Trastuzumab) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer
  Waratah; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Adelaide; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Brisbane; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Fitzroy; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Geelong; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Heidelberg; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Malvern; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Melbourne; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Nambour; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Parkville; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Perth; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Port Macquarie; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  St. Leonards; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Sydney; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Waratah; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Wodonga; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Wollongong; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Adelaide; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Brisbane; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Campbelltown; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Frankston; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Heidelberg; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Liverpool; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Malvern; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Melbourne; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Milton; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Perth; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  St. Leonards; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Sydney; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Wollongong; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Adelaide; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Fitzroy; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Frankston; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Geelong; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Heidelberg; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Liverpool; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Melbourne; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Parkville; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Perth; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Sydney; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Toowoomba; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Waratah; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Wodonga; Research Site:
  
  
• Chronic Lymphocytic Leukemia: Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
  Adelaide; Research Site
  
  
• Chronic Lymphocytic Leukemia: Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
  Ashford; Research Site
  
  
• Chronic Lymphocytic Leukemia: Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
  Brisbane; Research Site
  
  
• Chronic Lymphocytic Leukemia: Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
  Clayton; Research Site
  
  
• Chronic Lymphocytic Leukemia: Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
  Freemantle; Research Site
  
  
• Chronic Lymphocytic Leukemia: Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
  Gosford; Research Site
  
  
• Chronic Lymphocytic Leukemia: Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
  Nedlands; Research Site
  
  
• Chronic Lymphocytic Leukemia: Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
  St. Leonards; Research Site
  
  
• Chronic Lymphocytic Leukemia: Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
  Waratah; Research Site
  
  
• Chronic Lymphocytic Leukemia: Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
  Westmead; Research Site
  
  
• Chronic Lymphocytic Leukemia: Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
  Woodville; Research Site
  
  
• Chronic Lymphocytic Leukemia: Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
  Woolloongabba; Research Site
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Adelaide; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Brisbane; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Fitzroy; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Malvern; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Melbourne; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Perth; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Sydney; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Wollongong; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Adelaide; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Adelaide; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Brisbane; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Brisbane; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Darlinghurst; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Fremantle; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Heidelberg; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Kingswood; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Melbourne; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Melbourne; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Perth; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Port Macquarie; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  St. Leonards; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Sydney; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Sydney; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Waratah; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Waratah; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Wodonga; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.
  Fitzroy; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.
  Melbourne; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.
  Sydney; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Adelaide; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Brisbane; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Fitzroy; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Malvern; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Melbourne; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Perth; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Port Macquarie; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  St. Leonards; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Sydney; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Adelaide; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Bendigo; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Brisbane; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Fitzroy; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Melbourne; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Perth; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Port Macquarie; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  St. Leonards; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Sydney; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Wodonga; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Adelaide; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Melbourne; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Perth; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Port Macquarie; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Sydney; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Wollongong; Research Site:
  
  
• Gastric Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.
  Adelaide; Research Site:
  
  
• Gastric Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.
  Heidelberg; Research Site:
  
  
• Gastric Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.
  Melbourne; Research Site:
  
  
• Gastric Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.
  Sydney; Research Site:
  
  
• Gastric Cancer: ToGA study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer
  Adelaide; Research Site:
  
  
• Gastric Cancer: ToGA study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer
  Brisbane; Research Site:
  
  
• Gastric Cancer: ToGA study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer
  Melbourne; Research Site:
  
  
• Gastric Cancer: ToGA study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer
  Perth; Research Site:
  
  
• Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
  Adelaide; Research Site:
  
  
• Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
  Brisbane; Research Site:
  
  
• Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
  Fitzroy; Research Site:
  
  
• Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
  Frankston; Research Site:
  
  
• Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
  Fremantle; Research Site:
  
  
• Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
  Geelong; Research Site:
  
  
• Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
  Gosford; Research Site:
  
  
• Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
  Liverpool; Research Site:
  
  
• Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
  Melbourne; Research Site:
  
  
• Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
  Newcastle; Research Site:
  
  
• Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
  Perth; Research Site:
  
  
• Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
  St. Leonards; Research Site:
  
  
• Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
  Sydney; Research Site:
  
  
• Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
  Waratah; Research Site:
  
  
• Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
  Wodonga; Research Site:
  
  
• Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
  Woolloongabba; Research Site:
  
  
• Lymphocytic Leukemia, Chronic: A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
  Frankston; Research Site:
  
  
• Lymphocytic Leukemia, Chronic: A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
  Melbourne; Research Site:
  
  
• Lymphocytic Leukemia, Chronic: A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
  Sydney; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Adelaide; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Frankston; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Fremantle; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Melbourne; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Woolloongabba; Research Site:
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Waratah, NSW; Newcastle Melanoma Unit
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Nedlands; Sir Charles Gairdner Hospital
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  Wodonga, Vic; Murray Valley Private Hospital and Cancer Treatment Center
  
  
• Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
  South Brisbane, Qld; Mater Adult Hospital
  
  
• Mantle Cell Lymphoma: A Study of MabThera (Rituximab) for Treatment of Mantle Cell Non-Hodgkin's Lymphoma After Bone Marrow or Blood Stem Cell Transplantation
  Brisbane; Research Site:
  
  
• Mantle Cell Lymphoma: A Study of MabThera (Rituximab) for Treatment of Mantle Cell Non-Hodgkin's Lymphoma After Bone Marrow or Blood Stem Cell Transplantation
  Melbourne; Research Site:
  
  
• Mantle Cell Lymphoma: A Study of MabThera (Rituximab) for Treatment of Mantle Cell Non-Hodgkin's Lymphoma After Bone Marrow or Blood Stem Cell Transplantation
  Parkville; Research Site:
  
  
• Mantle Cell Lymphoma: A Study of MabThera (Rituximab) for Treatment of Mantle Cell Non-Hodgkin's Lymphoma After Bone Marrow or Blood Stem Cell Transplantation
  Perth; Research Site:
  
  
• Mantle Cell Lymphoma: A Study of MabThera (Rituximab) for Treatment of Mantle Cell Non-Hodgkin's Lymphoma After Bone Marrow or Blood Stem Cell Transplantation
  Sydney; Research Site:
  
  
• Mantle Cell Lymphoma: A Study of MabThera (Rituximab) for Treatment of Mantle Cell Non-Hodgkin's Lymphoma After Bone Marrow or Blood Stem Cell Transplantation
  Woolloongabba; Research Site:
  
  
• Melanoma: Elesclomol (STA-4783) With Paclitaxel versus Paclitaxel Alone in Melanoma
  Adelaide, South Australia; Medical Oncology
  
  
• Melanoma: Elesclomol (STA-4783) With Paclitaxel versus Paclitaxel Alone in Melanoma
  Fremantle; Fremantle Hospital
  
  
• Melanoma: Elesclomol (STA-4783) With Paclitaxel versus Paclitaxel Alone in Melanoma
  Hobart, Tasmania; Royal Hobart Hospital
  
  
• Melanoma: Elesclomol (STA-4783) With Paclitaxel versus Paclitaxel Alone in Melanoma
  Lismore, NS; Lismore Base Hospital, Cancer Care & Haematology Unit
  
  
• Melanoma: Elesclomol (STA-4783) With Paclitaxel versus Paclitaxel Alone in Melanoma
  North Sydney; Patricia Ritchie Centre for Cancer Care and Research
  
  
• Melanoma: Elesclomol (STA-4783) With Paclitaxel versus Paclitaxel Alone in Melanoma
  Redcliffe; Redcliffe Hospital
  
  
• Melanoma: Elesclomol (STA-4783) With Paclitaxel versus Paclitaxel Alone in Melanoma
  Tweed Heads; The Tweed Hospital
  
  
• Melanoma: Elesclomol (STA-4783) With Paclitaxel versus Paclitaxel Alone in Melanoma
  Waratah; Newcastle Melanoma Unit
  
  
• Melanoma: Elesclomol (STA-4783) With Paclitaxel versus Paclitaxel Alone in Melanoma
  Westmead; Department of Medical Oncology
  
  
• Melanoma: Elesclomol (STA-4783) With Paclitaxel versus Paclitaxel Alone in Melanoma
  Wollongong; Clinical Trials
  
  
• Melanoma: Elesclomol (STA-4783) With Paclitaxel versus Paclitaxel Alone in Melanoma
  Wooloongabba; Princess Alexandra Hospital
  
  
• Metastatic Melanoma: Elesclomol (STA-4783) With Paclitaxel versus Paclitaxel Alone in Melanoma
  Adelaide, South Australia; Medical Oncology
  
  
• Metastatic Melanoma: Elesclomol (STA-4783) With Paclitaxel versus Paclitaxel Alone in Melanoma
  Fremantle, WA; Fremantle Hospital
  
  
• Metastatic Melanoma: Elesclomol (STA-4783) With Paclitaxel versus Paclitaxel Alone in Melanoma
  Hobart, Tasmania; Royal Hobart Hospital
  
  
• Metastatic Melanoma: Elesclomol (STA-4783) With Paclitaxel versus Paclitaxel Alone in Melanoma
  Lismore, NS; Lismore Base Hospital, Cancer Care & Haematology Unit
  
  
• Metastatic Melanoma: Elesclomol (STA-4783) With Paclitaxel versus Paclitaxel Alone in Melanoma
  North Sydney; Patricia Ritchie Centre for Cancer Care and Research
  
  
• Metastatic Melanoma: Elesclomol (STA-4783) With Paclitaxel versus Paclitaxel Alone in Melanoma
  Redcliffe; Redcliffe Hospital
  
  
• Metastatic Melanoma: Elesclomol (STA-4783) With Paclitaxel versus Paclitaxel Alone in Melanoma
  Tweed Heads; The Tweed Hospital
  
  
• Metastatic Melanoma: Elesclomol (STA-4783) With Paclitaxel versus Paclitaxel Alone in Melanoma
  Waratah; Newcastle Melanoma Unit
  
  
• Metastatic Melanoma: Elesclomol (STA-4783) With Paclitaxel versus Paclitaxel Alone in Melanoma
  Westmead; Department of Medical Oncology
  
  
• Metastatic Melanoma: Elesclomol (STA-4783) With Paclitaxel versus Paclitaxel Alone in Melanoma
  Wollongong; Clinical Trials
  
  
• Metastatic Melanoma: Elesclomol (STA-4783) With Paclitaxel versus Paclitaxel Alone in Melanoma
  Wooloongabba; Princess Alexandra Hospital
  
  
• Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
  Adelaide; Research Site:
  
  
• Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
  Ballarat; Research Site:
  
  
• Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
  Brisbane; Research Site:
  
  
• Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
  Canberra; Research Site:
  
  
• Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
  Darlinghurst; Research Site:
  
  
• Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
  Fitzroy; Research Site:
  
  
• Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
  Frankston; Research Site:
  
  
• Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
  Fremantle; Research Site:
  
  
• Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
  Geelong; Research Site:
  
  
• Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
  Gosford; Research Site:
  
  
• Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
  Heidelberg; Research Site:
  
  
• Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
  Hobart; Research Site:
  
  
• Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
  Melbourne; Research Site:
  
  
• Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
  Newcastle; Research Site:
  
  
• Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
  Parkville; Research Site:
  
  
• Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
  Perth; Research Site:
  
  
• Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
  St. Leonards; Research Site:
  
  
• Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
  Sydney; Research Site:
  
  
• Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
  Townsville; Research Site:
  
  
• Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
  Wodonga; Research Site:
  
  
• Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
  Wollongong; Research Site:
  
  
• Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
  Woolloongabba; Research Site:
  
  
• Non-Hodgkin's Lymphoma: A Study of Ocrelizumab in Patients With Follicular Non-Hodgkin's Lymphoma (NHL)
  Melbourne; Research Site:
  
  
• Non-Hodgkin's Lymphoma: A Study of Ocrelizumab in Patients With Follicular Non-Hodgkin's Lymphoma (NHL)
  Perth; Research Site:
  
  
• Non-Hodgkin's Lymphoma: A Study of Ocrelizumab in Patients With Follicular Non-Hodgkin's Lymphoma (NHL)
  Woolloongabba; Research Site:
  
  
• Non-Hodgkin's Lymphoma: MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
  Brisbane; Research Site:
  
  
• Non-Hodgkin's Lymphoma: MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
  Liverpool; Research Site:
  
  
• Non-Hodgkin's Lymphoma: MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
  Perth; Research Site:
  
  
• Non-Hodgkin's Lymphoma: MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
  South Brisbane; Research Site:
  
  
• Non-Hodgkin's Lymphoma: MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
  Wollongong; Research Site:
  
  
• Non-Hodgkin's Lymphoma: The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
  Herston, QLD; Research Site
  
  
• Non-Hodgkin's Lymphoma: The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
  Herston, QLD; Research Site
  
  
• Non-Hodgkin's Lymphoma: The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
  South Brisbane QLD; Research Site
  
  
• Non-Hodgkin's Lymphoma: The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
  Woodville South SA; Research Site
  
  
• Non-Hodgkin's Lymphoma: The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
  Frankston, VIC; Research Site
  
  
• Non-Hodgkin's Lymphoma: The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
  Darlinghurst, NSW; Research Site
  
  
• Non-Hodgkin's Lymphoma: The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
  Frankston, Melbourne; Research Site
  
  
• Non-Hodgkin's Lymphoma: The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
  SouthPort, Goldcoast; Research Site
  
  
• Non-Hodgkin's Lymphoma: The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
  Ashford, SA; Research Site
  
  
• Non-Small Cell Lung Cancer: A Pilot Study of FDG- and FLT PET in Patients With Non-Small Cell Lung Cancer Treated with Tarceva (Erlotinib).
  Brisbane; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Pilot Study of FDG- and FLT PET in Patients With Non-Small Cell Lung Cancer Treated with Tarceva (Erlotinib).
  Chermside; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Pilot Study of FDG- and FLT PET in Patients With Non-Small Cell Lung Cancer Treated with Tarceva (Erlotinib).
  Heidelberg; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Pilot Study of FDG- and FLT PET in Patients With Non-Small Cell Lung Cancer Treated with Tarceva (Erlotinib).
  Melbourne; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
  Adelaide; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
  Fitzroy; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
  Melbourne; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
  St. Leonards; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
  Brisbane; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
  Chermside; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
  Geelong; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
  Malvern; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
  Melbourne; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
  Perth; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
  St. Leonards; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
  Sydney; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
  Tugun; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
  Waratah; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
  Wodonga; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  Adelaide; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  Brisbane; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  Canberra; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  Melbourne; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  Parkville; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  Perth; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  Sydney; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  Tugun; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  Wollongong; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
  Auchenflower; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
  Chermside; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
  Greenslopes; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
  Lismore; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
  Melbourne; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
  Parkville; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
  Perth; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
  Randwick; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
  Richmond; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
  St. Leonards; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
  Sydney; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
  Wodonga; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
  Wollongong; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
  Adelaide; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
  Fitzroy; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
  Geelong; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
  Melbourne; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
  St. Leonards; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
  Waratah; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
  Adelaide; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
  Fitzroy; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
  Geelong; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
  Melbourne; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
  St. Leonards; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
  Waratah; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.
  Geelong; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.
  Melbourne; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.
  Campbelltown; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.
  Liverpool; Research Site:
  
  
• Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.
  Sydney; Research Site:
  
  
• Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
  Adelaide; Research Site:
  
  
• Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
  Brisbane; Research Site:
  
  
• Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
  Frankston; Research Site:
  
  
• Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
  Fremantle; Research Site:
  
  
• Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
  Geelong; Research Site:
  
  
• Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
  Malvern; Research Site:
  
  
• Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
  Melbourne; Research Site:
  
  
• Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
  Perth; Research Site:
  
  
• Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
  St. Leonards; Research Site:
  
  
• Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
  Sydney; Research Site:
  
  
• Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
  Tugun; Research Site:
  
  
• Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
  Waratah; Research Site:
  
  
• Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
  Wodonga; Research Site:
  
  
• Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
  Wollongong; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Melbourne; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  St. Leonards; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Sydney; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Adelaide; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Ballarat; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Brisbane; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Canberra; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Frankston; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Liverpool; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  St. Leonards; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Sydney; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Adelaide; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Heidelberg; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Melbourne; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  St. Leonards; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Sydney; Research Site:
  
  
• Renal Cell Cancer: A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
  Adelaide; Research Site:
  
  
• Renal Cell Cancer: A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
  Brisbane; Research Site:
  
  
• Renal Cell Cancer: A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
  Canberra; Research Site:
  
  
• Renal Cell Cancer: A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
  Frankston; Research Site:
  
  
• Renal Cell Cancer: A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
  Melbourne; Research Site:
  
  
• Renal Cell Cancer: A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
  Perth; Research Site:
  
  
• Renal Cell Cancer: A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
  Sydney; Research Site:
  
  
• Sarcoma: A Study of R1507 in Patients With Recurrent or Refractory Sarcoma.
  Adelaide; Research Site:
  
  
• Sarcoma: A Study of R1507 in Patients With Recurrent or Refractory Sarcoma.
  Melbourne; Research Site:
  
  
• Sarcoma: A Study of R1507 in Patients With Recurrent or Refractory Sarcoma.
  Sydney; Research Site:
  
  
• Sarcoma: A Study of R1507 in Patients With Recurrent or Refractory Sarcoma.
  Westmead; Research Site:
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Box Hill; Department Of Medical Oncology, Box Hill Hospital
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Coffs Harbour; Coffs Harbour Health Campus
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Newcastle; David Maddison Building
  
  
• Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
  Port Macquarie; Port Macquarie Base Hospital
  
  

Austria

• Bladder Cancer: A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
  Linz; Research Site
  
  
• Bladder Cancer: A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
  Salzburg; Research Site
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Primary Breast Cancer
  Salzburg; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Graz; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Salzburg; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Vöcklabruck; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Wien; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Graz; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Salzburg; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Vöcklabruck; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Wien; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Bludesch; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Bregenz; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Dornbirn; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Graz; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Hall In Tirol; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Innsbruck; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Klagenfurt; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Krems; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Kufstein; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Leoben; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Linz; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Ried-Innkreis; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  St Pölten; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  St Veit an der Glan; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Steyr; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Villach; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Wels; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Wien; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Wiener Neustadt; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Zams; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer
  Wien; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
  Klagenfurt; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
  Salzburg; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
  Vöcklabruck; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
  Wien; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
  Wien; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Bludesch; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Graz; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Innsbruck; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Leoben; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Salzburg; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Wels; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Wien; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Wiener Neustadt; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Wolfsberg; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Graz; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Innsbruck; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Klagenfurt; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Kufstein; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Leoben; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Linz; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Oberwart; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Salzburg; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Vöcklabruck; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Wels; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Wien; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Bludesch; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Graz; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Innsbruck; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Klagenfurt; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Linz; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Salzburg; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  St Veit an der Glan; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Villach; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Vöcklabruck; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Wels; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Wien; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Wiener Neustadt; Research Site:
  
  
• Chronic Lymphocytic Leukemia: Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
  Graz; Research Site
  
  
• Chronic Lymphocytic Leukemia: Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
  Herston; Research Site
  
  
• Chronic Lymphocytic Leukemia: Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
  Wien; Research Site
  
  
• Chronic Lymphocytic Leukemia: Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chro